Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RARalpha

Sake van Wageningen1, Marleen C Breems-de Ridder, Jeannet Nigten

  • 1Central Hematology Laboratory and Department of Hematology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

Blood
|November 21, 2007
PubMed

Insights

The PML-RARalpha oncoprotein in acute myeloid leukemia silences gene differentiation. Unexpectedly, it activates ID1 and ID2 genes via transcription factors, revealing a novel gain-of-function mechanism.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematopoiesis

Background:

  • PML-RARalpha is a key oncogene in acute myeloid leukemia (AML), driving disease by disrupting normal cellular differentiation.
  • Retinoic acid (RA) regulates PML-RARalpha activity: low RA causes gene silencing and blocks differentiation, while high RA forces terminal differentiation.
  • Understanding RARalpha target genes is crucial for controlling hematopoietic cell proliferation and differentiation in both normal and malignant states.

Purpose of the Study:

  • To investigate the transcriptional regulatory role of the PML-RARalpha fusion protein beyond known RARalpha target genes.
  • To identify novel target genes and mechanisms regulated by PML-RARalpha.
  • To elucidate the gain-of-function mechanisms of the PML-RARalpha oncoprotein.

Main Methods:

  • Analysis of gene expression patterns in response to PML-RARalpha.
  • Promoter activity assays for ID1 and ID2 genes.
  • Investigation of interactions between PML-RARalpha, Sp1, and NF-Y transcription factors.

Main Results:

  • PML-RARalpha activates the ID1 and ID2 gene promoters, a function not observed with wild-type RARalpha/RXR.
  • This activation occurs independently of direct DNA binding by PML-RARalpha.
  • PML-RARalpha interacts with Sp1 and NF-Y transcription factors to regulate this novel class of target genes.

Conclusions:

  • The PML-RARalpha oncoprotein exhibits a gain-of-function by regulating a novel set of target genes, including ID1 and ID2.
  • This regulation is mediated through interactions with Sp1 and NF-Y, independent of direct DNA binding.
  • These findings offer new insights into the molecular mechanisms of AML pathogenesis and potential therapeutic strategies.

Related Concept Videos

Eukaryotic Transcription Activators02:42

Eukaryotic Transcription Activators

Transcription activators are proteins that promote the transcription of genes from DNA to RNA. In most cases, these proteins contain two separate domains ‒ a domain that binds to DNA and a domain for activating transcription; however, in some cases, a single domain is responsible for both binding and activation of transcription, as seen in the glucocorticoid receptor and MyoD.
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These domains are...
RNA Polymerase II Accessory Proteins02:36

RNA Polymerase II Accessory Proteins

Proteins that regulate transcription can do so either via direct contact with RNA Polymerase or through indirect interactions facilitated by adaptors, mediators, histone-modifying proteins, and nucleosome remodelers. Direct interactions to activate transcription is seen in bacteria as well as in some eukaryotic genes. In these cases, upstream activation sequences are adjacent to the promoters, and the activator proteins interact directly with the transcriptional machinery. For example, in...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...